FDA Adverse Event Malfunction Summary report: N

FT3 - FREE TRIIODOTHYRONINE

MDR report key: 5066940 · Received September 10, 2015

Report

Report Number
1823260-2015-04113
Event Type
Malfunction
Date Received
September 10, 2015
Date of Event
August 11, 2015
Report Date
September 10, 2015
Manufacturer
ROCHE DIAGNOSTICS
Product Code
CDP
PMA / PMN Number
K963127
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

THIS EVENT OCCURRED IN (B)(6).

Description of Event or Problem · 1

THE CUSTOMER QUESTIONED RESULTS FROM 1 PATIENT SAMPLE TESTED FOR THYROTROPIN (TSH), FREE THYROXINE (FT4) AND FREE TRIIODOTHYRONINE (FT3). THE CUSTOMER HAD COMPARED RESULTS FROM THEIR E 170 ANALYZER TO AN EXTERNAL LABORATORY WHERE A LUMIPULSE ANALYZER WAS USED. THE CUSTOMER PROVIDED THE SAMPLE FOR INVESTIGATION. OF THE DATA PROVIDED, ERRONEOUS FT4 AND FT3 RESULTS WERE IDENTIFIED BETWEEN THE CUSTOMER'S E 170 ANALYZER, A LUMIPULSE ANALYZER, AN E 170 ANALYZER USED AT THE INVESTIGATION SITE AND AN E411 ANALYZER USED AT THE INVESTIGATION SITE. IT IS NOT KNOWN IF ERRONEOUS RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. THIS MEDWATCH WILL COVER FT3. REFER TO MEDWATCH WITH (B)(6) FOR INFORMATION ON THE FT4 ERRONEOUS RESULTS. NO ADVERSE EVENT WAS REPORTED. THE E 170 ANALYZER SERIAL NUMBER WAS (B)(4). THE E411 ANALYZER SERIAL NUMBER WAS (B)(4). THE FT3 REAGENT LOT NUMBER USED WITH THE E170 ANALYZER AT THE INVESTIGATION SITE WAS 185694 WITH AN EXPIRATION DATE OF 05/2016. THE FT3 REAGENT LOT NUMBER USED WITH THE E411 ANALYZER AT THE INVESTIGATION SITE WAS 183221 WITH AN EXPIRATION DATE OF 01/2016. THE SERIAL NUMBER FOR THE CUSTOMER'S E 170 ANALYZER WAS (B)(4). A SPECIFIC ROOT CAUSE COULD NOT BE IDENTIFIED. THERE WAS NOT ENOUGH SAMPLE VOLUME LEFT TO COMPLETE THE INVESTIGATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
598943 FT3 - FREE TRIIODOTHYRONINE RADIOIMMUNOASSAY, TOTAL TRIIODOTHYRONINE CDP ROCHE DIAGNOSTICS NA ASKU

Patients

Seq Age Sex Outcome Treatment
1